000294724 001__ 294724
000294724 005__ 20241201014156.0
000294724 0247_ $$2doi$$a10.1016/S0140-6736(24)01884-1
000294724 0247_ $$2pmid$$apmid:39527960
000294724 0247_ $$2ISSN$$a0140-6736
000294724 0247_ $$2ISSN$$a0023-7507
000294724 0247_ $$2ISSN$$a1474-547X
000294724 0247_ $$2altmetric$$aaltmetric:170230036
000294724 037__ $$aDKFZ-2024-02457
000294724 041__ $$aEnglish
000294724 082__ $$a610
000294724 1001_ $$aKwiatkowski, Janet L$$b0
000294724 245__ $$aBetibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial.
000294724 260__ $$aLondon [u.a.]$$bElsevier$$c2024
000294724 3367_ $$2DRIVER$$aarticle
000294724 3367_ $$2DataCite$$aOutput Types/Journal article
000294724 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732892458_27947
000294724 3367_ $$2BibTeX$$aARTICLE
000294724 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294724 3367_ $$00$$2EndNote$$aJournal Article
000294724 520__ $$aTransfusion-dependent β-thalassaemia (TDT) is a severe disease, resulting in lifelong blood transfusions, iron overload, and associated complications. Betibeglogene autotemcel (beti-cel) gene therapy uses autologous haematopoietic stem and progenitor cells (HSPCs) transduced with BB305 lentiviral vector to enable transfusion independence.HGB-212 was a non-randomised, multicentre, single-arm, open-label, phase 3 study of beti-cel in patients with TDT conducted at eight centres in France, Germany, Greece, Italy, the UK, and the USA. Patients with β0/β0, β0/β+IVS-I-110, or β+IVS-I-110/β+IVS-I-110 genotypes, clinically stable TDT, and a transfusion history of at least 100 mL/kg per year of packed red blood cells (pRBCs) or at least eight transfusions of pRBCs per year in the 2 years before enrolment were eligible for participation. After undergoing HSPC mobilisation and busulfan-based, pharmacokinetic-adjusted myeloablative conditioning, patients were infused with beti-cel and followed up for 24 months. The primary efficacy outcome was transfusion independence, defined as weighted average haemoglobin level of 9 g/dL or above without pRBC transfusions for 12 or more months. The primary outcome was measured in all patients who received an infusion of beti-cel (transplant population); safety was evaluated in all patients who initiated study treatment (intention-to-treat population). Patients were eligible to enrol in the ongoing 13-year long-term follow-up study (for a total of 15 years), LTF-303 (registered at ClinicalTrials.gov, NCT02633943). This trial, HGB-212, was registered at ClinicalTrials.gov (NCT03207009), and is complete.From June 8, 2017, to March 12, 2020, 20 patients were screened for eligibility. One patient was ineligible and one withdrew consent before HSPC mobilisation and myeloablative conditioning. Of the 18 patients who received beti-cel, ten (56%) were male and eight (44%) were female; 13 (72%) were younger than 18 years at the time of informed consent, and five (28%) were older than 18 years. 12 (67%) patients had β0/β0 genotypes, three (17%) had β0/ β+IVS-I-110, and three (17%) had β+IVS-I-110/β+IVS-I-110. As of Jan 30, 2023, all patients enrolled in the long-term follow-up study and the median follow-up was 47·9 months (range 23·8-59·0). All 18 patients were evaluable for transfusion independence, with 16 (89%) of 18 reaching and maintaining transfusion independence to last follow=up (estimated effect size 89·9% [95% CI 65·3-98·6]). All patients had at least one adverse event after beti-cel infusion. There were no serious adverse events considered to be related to beti-cel, and no deaths.These data demonstrate that beti-cel can allow patients with genotypes that cause severe β-thalassaemia (β0/β0, β0/β+IVS-I-110, or β+IVS-I-110/β+IVS-I-110) to reach transfusion independence. Beti-cel offers the potential to attain near-normal haemoglobin levels for those with severe forms of TDT, and a potentially curative option without the risks and limitations of allogeneic HSPC transplantation. Patients are being followed up for a total of 15 years to assess the durability of transfusion independence and long-term safety profile of beti-cel.Bluebird Bio, Somerville, MA, USA.
000294724 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000294724 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294724 7001_ $$aWalters, Mark C$$b1
000294724 7001_ $$aHongeng, Suradej$$b2
000294724 7001_ $$aYannaki, Evangelia$$b3
000294724 7001_ $$0P:(DE-He78)ca062b8db1ee864e03f0a92897728df3$$aKulozik, Andreas$$b4$$udkfz
000294724 7001_ $$aKunz, Joachim B$$b5
000294724 7001_ $$aSauer, Martin G$$b6
000294724 7001_ $$aThrasher, Adrian J$$b7
000294724 7001_ $$aThuret, Isabelle$$b8
000294724 7001_ $$aLal, Ashutosh$$b9
000294724 7001_ $$aTao, Ge$$b10
000294724 7001_ $$aAli, Shamshad$$b11
000294724 7001_ $$aThakar, Himal L$$b12
000294724 7001_ $$aElliot, Heidi$$b13
000294724 7001_ $$aLodaya, Ankit$$b14
000294724 7001_ $$aLee, Ji$$b15
000294724 7001_ $$aColvin, Richard A$$b16
000294724 7001_ $$aLocatelli, Franco$$b17
000294724 7001_ $$aThompson, Alexis A$$b18
000294724 773__ $$0PERI:(DE-600)1476593-7$$a10.1016/S0140-6736(24)01884-1$$gVol. 404, no. 10468, p. 2175 - 2186$$n10468$$p2175 - 2186$$tThe lancet$$v404$$x0140-6736$$y2024
000294724 909CO $$ooai:inrepo02.dkfz.de:294724$$pVDB
000294724 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ca062b8db1ee864e03f0a92897728df3$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000294724 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000294724 9141_ $$y2024
000294724 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000294724 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bLANCET : 2022$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000294724 915__ $$0StatID:(DE-HGF)9990$$2StatID$$aIF >= 90$$bLANCET : 2022$$d2023-10-21
000294724 9201_ $$0I:(DE-He78)A400-20160331$$kA400$$lKKE Pädiatrische Leukämie$$x0
000294724 980__ $$ajournal
000294724 980__ $$aVDB
000294724 980__ $$aI:(DE-He78)A400-20160331
000294724 980__ $$aUNRESTRICTED